Arcellx Investor Sells Out After Gilead Completes $115‑Plus‑CVR Acquisition

Context On February 22, 2026 Gilead Sciences Inc. (NASDAQ:GILD) announced a merger agreement with Arcellx, Inc. (NASDAQ:ARCL). The deal stipulated a cash payment of $115 per share, plus one CVR per share that could deliver an additional $5 if a future milestone is met. The agreement required a tender offer, a formal bid to purchase all outstanding shares, followed by a merger in which Gilead’s subsidiary Ravens Sub, Inc. would merge into Arcellx, leaving Arcellx as a wholly owned Gilead subsidiary.

Key Facts - The tender offer closed on April 28, 2026. Each ARCL share was converted into the right to receive $115 in cash and one CVR worth up to $5. - At the effective merger time, all unexercised stock options with exercise prices below $115 were cancelled and converted into cash plus a CVR per option. Likewise, all outstanding restricted stock units (RSUs) were cancelled and converted into cash plus a CVR per RSU. - The reporting person tendered every ARCL share held and, after the option and RSU conversions, held no remaining shares or voting rights in Arcellx. - Post‑closing, Arcellx’s market capitalization fell to zero as it became a wholly owned subsidiary; Gilead’s market cap remains around $115 billion. - ARCL’s share price had traded at $112 prior to the offer, representing a 2.7% premium to the cash component alone.

What It Means The exit of a significant shareholder underscores the finality of the transaction. By converting options and RSUs into cash and CVRs, the merger eliminated any residual equity exposure for insiders, simplifying Gilead’s ownership structure. The CVR mechanism ties a modest $5 upside to the achievement of a predefined clinical or regulatory milestone, aligning future payouts with Arcellx’s product development progress. For investors, the deal adds a new biologics platform to Gilead’s pipeline, potentially expanding its oncology and immunology portfolio. The cash outlay of $115 per share values Arcellx at roughly $4.2 billion, a figure that reflects both current assets and the anticipated value of the contingent milestone.

Looking Ahead Watch for the CVR trigger event—Gilead will disclose whether the $5 per share milestone is met, which could add up to $21 million to the total consideration and affect Gilead’s earnings guidance.